These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 7623949)

  • 1. Growth rate of intracranial meningioma: tumor doubling time and proliferating cell nuclear antigen staining index.
    Ide M; Jimbo M; Yamamoto M; Umebara Y; Hagiwara S; Kubo O
    Neurol Med Chir (Tokyo); 1995 May; 35(5):289-93. PubMed ID: 7623949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proliferating cell nuclear antigen (PCNA) immunostaining as an alternative to bromodeoxyuridine (BrdU) immunostaining for brain tumours in paraffin embedded sections.
    Sasaki A; Naganuma H; Kimura R; Isoe S; Nakano S; Nukui H; Suzuki K; Kawaoi A
    Acta Neurochir (Wien); 1992; 117(3-4):178-81. PubMed ID: 1357920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of proliferating cell nuclear antigen in predicting recurrence of intracranial meningioma.
    Cobb MA; Husain M; Andersen BJ; al-Mefty O
    J Neurosurg; 1996 Jan; 84(1):85-90. PubMed ID: 8613841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the proliferating cell nuclear antigen and clinicopathological features in intracranial meningiomas.
    Kim CH; Cheong JH; Bak KH; Kim JM; Oh SJ
    J Clin Neurosci; 2001 May; 8 Suppl 1():44-8. PubMed ID: 11386825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proliferative potential of meningiomas evaluated by proliferating cell nuclear antigen expression.
    Nakabayashi H; Sakaguchi M; Katsuyama J; Hakuba A
    J Neurooncol; 1995; 24(3):209-17. PubMed ID: 7595751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PCNA, Ki-67 and hTERT in residual benign meningiomas.
    Maes L; Kalala JP; Cornelissen M; De Ridder L
    In Vivo; 2006; 20(2):271-5. PubMed ID: 16634530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Invasive meningioma: a tumour with high proliferating and "recurrence" potential.
    Suwa T; Kawano N; Oka H; Ito H; Kameya T
    Acta Neurochir (Wien); 1995; 136(3-4):127-31. PubMed ID: 8748841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proliferating cell nuclear antigen (PCNA) in atypical and malignant meningiomas.
    Zimmer C; Gottschalk J; Cervos-Navarro J; Martin H; Beil M; Jautzke G
    Pathol Res Pract; 1992 Dec; 188(8):951-8. PubMed ID: 1363764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical expression of proliferating cell nuclear antigen (PCNA) in intracranial glioma and meningioma.
    Shih YH; Kadota Y; Sato K; Sueyoshi N; Shirai T
    Zhonghua Yi Xue Za Zhi (Taipei); 1994 Apr; 53(4):193-7. PubMed ID: 7911730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA topoisomerase IIalpha expression correlates with cell proliferation but not with recurrence in intracranial meningiomas.
    Konstantinidou AE; Patsouris E; Korkolopoulou P; Kavantzas N; Mahera H; Davaris P
    Histopathology; 2001 Oct; 39(4):402-8. PubMed ID: 11683942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracranial meningeal tumours in childhood: a clinicopathologic study including MIB-1 immunohistochemistry.
    Demirtaş E; Erşahin Y; Yilmaz F; Mutluer S; Veral A
    Pathol Res Pract; 2000; 196(3):151-8. PubMed ID: 10729919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive evaluation of the malignant potential of intracranial meningiomas performed using proton magnetic resonance spectroscopy.
    Shino A; Nakasu S; Matsuda M; Handa J; Morikawa S; Inubushi T
    J Neurosurg; 1999 Dec; 91(6):928-34. PubMed ID: 10584837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential doubling time and tumour doubling time in meningiomas and neurinomas.
    Nakasu S; Nakasu Y; Nakajima M; Yokoyama M; Matsuda M; Handa J
    Acta Neurochir (Wien); 1996; 138(6):763-70. PubMed ID: 8836295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apoptosis detected with monoclonal antibody to single-stranded DNA is a predictor of recurrence in intracranial meningiomas.
    Konstantinidou A; Korkolopoulou P; Patsouris E; Mahera H; Hranioti S; Kotsiakis X; Davaris P
    J Neurooncol; 2001 Oct; 55(1):1-9. PubMed ID: 11804277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapidly growing histologically benign meningiomas: cell kinetic and deoxyribonucleic acid ploidy features: report of three cases.
    Kudoh C; Sugiura K; Yoshimizu N; Detta A
    Neurosurgery; 1995 Nov; 37(5):998-1000; discussion 1000-1. PubMed ID: 8559351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclin D1 immunoreactivity in meningiomas.
    Milenković S; Marinkovic T; Jovanovic MB; Djuricic S; Berisavac II; Berisavac I
    Cell Mol Neurobiol; 2008 Sep; 28(6):907-13. PubMed ID: 18379871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can recurrence of meningiomas be predicted?
    Kalala JP; Benoit D; De Ridder L
    Anticancer Res; 2004; 24(4):2319-24. PubMed ID: 15330178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical detection of progesterone receptors and the correlation with Ki-67 labeling indices in paraffin-embedded sections of meningiomas.
    Nagashima G; Aoyagi M; Wakimoto H; Tamaki M; Ohno K; Hirakawa K
    Neurosurgery; 1995 Sep; 37(3):478-82; discussion 483. PubMed ID: 7501113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of PDGF and its receptor as well as their relationship to proliferating activity and apoptosis of meningiomas in human meningiomas.
    Yang SY; Xu GM
    J Clin Neurosci; 2001 May; 8 Suppl 1():49-53. PubMed ID: 11386826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA topoisomerase II-alpha and cyclin A immunoexpression in meningiomas and its prognostic significance: an analysis of 263 cases.
    Korshunov A; Shishkina L; Golanov A
    Arch Pathol Lab Med; 2002 Sep; 126(9):1079-86. PubMed ID: 12204057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.